- Home
- PTGX vs ADMA Comparison
PTGX vs ADMA Comparison
Compare PTGX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | ADMA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 3.6B |
| IPO Year | 2016 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PTGX | ADMA |
|---|---|---|
| Price | $96.84 | $16.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $100.17 | $32.00 |
| AVG Volume (30 Days) | 551.4K | ★ 3.1M |
| Earning Date | 06-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $711.26 | $27.46 |
| Revenue Next Year | N/A | $21.11 |
| P/E Ratio | ★ N/A | $26.37 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $39.60 | $13.76 |
| 52 Week High | $100.00 | $25.67 |
Technical Indicators
Market Signals| Indicator | PTGX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 53.14 |
| Support Level | $76.63 | $15.35 |
| Resistance Level | $100.00 | $17.53 |
| Average True Range (ATR) | 4.24 | 0.82 |
| MACD | 0.39 | 0.08 |
| Stochastic Oscillator | 81.98 | 68.97 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.